Loading clinical trials...

Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology | Clinical Trials | Clareo Health

RECRUITINGNA

Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology

NCT06033183•Neolys

View on ClinicalTrials.gov

Summary

Analysis of the individual radiosensitivity in pediatric oncology

Eligibility

Age

3 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes.
•Children or adolescents \> 3 years old and \< 18 years old
•Patient with an indication for radiotherapy as part of the primary tumor local control strategy
•Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used
•Patient affiliated with a social security scheme
•Patient and/or parents or holders of parental authority having dated and signed an informed consent

Exclusion Criteria

•Patients with contraindications to blood sampling
•Patients with contraindications to radiotherapy
•Palliative radiotherapy
•Patient with previous RT treatment in the same area (re-irradiation)
•Patient with an indication of hypofractionated RT
•Patient follow-up not possible
•Persons deprived of liberty or under guardianship (including curatorship)
•\-

Locations (2)

Centre François Baclesse

Caen, France

Centre Oscar Lambret

Lille, France

Key Dates

Start Date

December 2, 2023

Primary Completion Date

August 30, 2027

Completion Date

October 30, 2027

Last Updated

November 22, 2024

Enrollment

100

ESTIMATED participants

Conditions

RadiosensitivityPediatric CancerRadiation Toxicity

Interventions

Blood sample

BIOLOGICAL

Contacts

Sandrine PEREIRA, PhD

CONTACT

0643957510 spereira@neolys-diagnostics.fr

Jennifer RUOS

CONTACT

jruos@fondation-force.fr

Lurbinectedin in FET-Fused Tumors

NCT05918640

Ewing SarcomaDesmoplastic Small Round Cell Tumor+2 more

View study

RECRUITING

Real World Pediatric Oncology Rehabilitation in Italy ( ReWori )

NCT07368582

Pediatric CancerPediatric Cancer Patients+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 22, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology

Inclusion Criteria

Exclusion Criteria

Lurbinectedin in FET-Fused Tumors

Real World Pediatric Oncology Rehabilitation in Italy ( ReWori )

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

Shared Decision Making on Radiation Dose for Lung Malignancies

Targeted Therapy to Increase RAI Uptake in Metastatic DTC